Literature DB >> 6314218

Action mechanism of timolol to lower the intraocular pressure in rabbits.

K Watanabe, G C Chiou.   

Abstract

The effect of timolol on the active transport system in the iris root-ciliary body of rabbits was studied to elucidate the action mechanism of timolol. Neither Na+-K+-adenosine triphosphatase (ATPase) nor Mg++-ATPase was inhibited by timolol at 1 X 10(-4) M concentration. None of the energy production parameters (oxygen consumption, glucose metabolism, and lactic acid formation) was inhibited by timolol either. Further, the biosynthesis of prostaglandins E2 and F2 alpha was not affected by timolol at 1 X 10(-3) M. The blood flow to the eye was measured with a 85Sr-microsphere method. It was found that the blood flow in the iris root-ciliary body and choroid was significantly reduced by a topical application of 0.25% timolol. The dopamine concentration in the iris root-ciliary body was reduced by timolol at 1 X 10(-5) M concentration. Neither epinephrine nor norepinephrine concentration was altered by timolol. The results indicate that timolol reduces the rate of aqueous humor formation through reduction of blood flow to the ciliary process rather than via the inhibition of the active transport system or that of prostaglandin biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314218     DOI: 10.1159/000265251

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  14 in total

Review 1.  Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  P E Battershill; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Dopamine-2 receptor blockade does not affect the ocular hypotensive action of timolol.

Authors:  Q A Mekki; P Turner
Journal:  Br J Ophthalmol       Date:  1988-08       Impact factor: 4.638

3.  Is topical haloperidol a useful glaucoma treatment?

Authors:  M J Lavin; V Andrews
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

4.  Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment.

Authors:  Shakiru O Alapafuja; Michael S Malamas; Vidyanand Shukla; Alexander Zvonok; Sally Miller; Laura Daily; Girija Rajarshi; Christina Yume Miyabe; Honrao Chandrashekhar; JodiAnne Wood; Sergiy Tyukhtenko; Alex Straiker; Alexandros Makriyannis
Journal:  Bioorg Med Chem       Date:  2018-11-03       Impact factor: 3.641

Review 5.  Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.

Authors:  M M Buckley; K L Goa; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

6.  Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

Authors:  Erin Lavik; Markus H Kuehn; Andrew J Shoffstall; Kristyn Atkins; Alina V Dumitrescu; Young H Kwon
Journal:  J Ocul Pharmacol Ther       Date:  2016-11-11       Impact factor: 2.671

7.  Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.

Authors:  Makoto Aihara; Fenghe Lu; Hisashi Kawata; Akihiro Iwata; Noriko Odani-Kawabata
Journal:  Jpn J Ophthalmol       Date:  2021-09-08       Impact factor: 2.447

8.  Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial.

Authors:  Nevin W El-Nimri; Sasan Moghimi; Rafaella C Penteado; Elham Ghahari; Diya Yang; Nicole Brye; James Proudfoot; Jiun L Do; Andrew Camp; Matthew Salcedo; Veronica Rubio; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2022-05-06       Impact factor: 5.488

9.  Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.

Authors:  Youichi Shinozaki; Kenji Kashiwagi; Kazuhiko Namekata; Akiko Takeda; Nobuhiko Ohno; Bernard Robaye; Takayuki Harada; Takeshi Iwata; Schuichi Koizumi
Journal:  JCI Insight       Date:  2017-10-05

Review 10.  Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus.

Authors:  Quang H Nguyen
Journal:  Patient Prefer Adherence       Date:  2014-06-12       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.